Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 728-732

  Gillham, M I ^a   Sundaram, S ^a   Laughton, C R ^a   Haworth, C S ^a   Bilton, D ^b   Foweraker, Juliet E ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Disc diffusion; Morphotypes; P. aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM COLONY; BACTERIUM CULTURE; BRONCHIECTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISK DIFFUSION; HUMAN; MICROBIAL MORPHOLOGY; PHENOTYPIC VARIATION; PSEUDOMONAS AERUGINOSA; SKIN CULTURE; SPUTUM ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; GENETIC VARIATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; YOUNG ADULT;

EID: 62549149444     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp007     Document Type: Article

References (11)

1. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4. Noncystic fibrosis bronchiectasis. Thorax 2008; 63: 269-76.
2. Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383-93.
3. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
4. Nguyen D, Singh PK. Evolving stealth: Genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc Natl Acad Sci USA 2006; 103: 8305-6.
5. Foweraker JE, Laughton CR, Brown DF J et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55: 921-7.
6. Maciá MD, Blanquer D, Togores B et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49: 3382-6.
7. Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol 2008; 6: 199-210.
8. May JR, Ingold A. Sensitivity of respiratory strains of Pseudomonas aeruginosa to carbenicillin. J Med Microbiol 1973; 6: 77-82.
9. Ramos-Aires J, Plésiat P, Kocjancic-Curty L et al. Selection of an antibiotic-hypersusceptible mutant of Pseudomonas aeruginosa: identification of the GlmR transcriptional regulator. Antimicrob Agents Chemother 2004; 48: 843-51.
10. Perry JD, Laine L, Hughes S et al. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother 2008; 61: 1057-61.
11. Smith AL, Fiel SB, Mayer-Hamblett N et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.